BARX2 and breast carcinoma: Moreover, focal Barx2 expression was observed at sites undergoing epithelial-mesenchymal transition and its aberrant expression has been reported in some malignant cancers with poor prognosis, such as ovarian cancer [15], hepatocellular carcinoma [16], and breast cancer [17].